Under the drug test, several batches of drugs were deactivation and recall

"Pharmaceutical Network Industry Dynamics" Recently, the State Drug Administration issued a "Notice on the Non-compliance of 18 batches of drugs (No. 73 of 2020)" (hereinafter referred to as "Notice").
, 18 batches of drugs produced by 11 pharmaceutical manufacturers will be suspended for use, recall and other risk control measures because they do not comply with the regulations.
, the reasons for non-compliance will also be investigated and effectively corrected.
After combing, these 18 batches of non-conforming drugs involved 10 kinds of drugs, there are 6 kinds of preparations, respectively, compound acetaminophen tablets, compound anti-eggplant aluminum hydroxide tablets, ginseng injection, injection with Ozagrain sodium, injection of sodium caro sulfon, injection of nida platinum
18 batches of drugs were suspended and recalled, reflecting not only the state's strict supervision of drugs, but also the quality of Chinese herbal medicines and their tablets is still a serious injury to the pharmaceutical industry.
it is understood that since this year, Fujian, Jiangxi, Shandong, Hunan, Shanxi and other provinces and cities have issued a drug quality announcement, which also involves a large number of unqualified Chinese herbal medicines and their drink tablets.
, on August 20, the State Drug Administration issued a circular on the non-compliance of 25 batches of drugs, and 25 batches of drugs produced by 20 pharmaceutical manufacturers did not comply with the regulations.
of them are Chinese medicine tablets.
, the drug regulatory department has asked relevant enterprises and units to take risk control measures such as suspension of sales and recall, to investigate the causes of non-compliance and to carry out effective rectification.
July 6, the Hubei Provincial Drug Administration issued the 2nd issue of the 2020 Drug Quality Bulletin.
the drug quality sampling, found that 65 batches did not meet the standards, including 4 preparations and raw materials, 61 kinds of Chinese herbal medicines (drink tablets).
at present, the municipal (state) market supervision and administration bureaus are also investigating and dealing with drugs and related units that do not meet the standards stipulated in the announcement, and the results and related circumstances will be reported in a timely manner in accordance with the provisions of the Drug Administration Law of the People's Republic of China.
in recent years, the state has paid more and more attention to the problem of Chinese medicine treatment.
as early as 2013 to carry out the drug "two dozen two construction" special action, a top-down food and drug safety "security war" began in the country.
While governments at all levels and drug regulatory departments have stepped up supervision, the professional market for Chinese herbal medicines, the production, circulation and use of Chinese medicine tablets and other links have indeed been greatly improved, and significant progress has been made.
according to the national sampling of the quality of Chinese herbal medicines and drink tablets, the pass rate in 2013-2018 is rising, from 64% in 2013 to 88% in 2018, and the quality has steadily improved.
It is worth noting, however, that due to the shortage of resources, expanding market demand, long industrial chain and other factors, the Chinese medicine industry still exists counterfeiting, counterfeit sales, illegal operation and other phenomena.
, the industry expects the country to do more and strengthen market supervision.
In general, the future of the State Drug Administration and the local drug regulatory bureau inspection work continued, there will inevitably be a big wave of drug focus supervision and inspection, targeted inspection coming, the relevant pharmaceutical companies with a lucky mentality, strengthen the quality and safety of drug production is the king of continuous operation.